These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Advances in the treatment of gastric cancer. Ilson DH Curr Opin Gastroenterol; 2020 Nov; 36(6):525-529. PubMed ID: 32889823 [TBL] [Abstract][Full Text] [Related]
5. Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma. Birla R; Hoara P; Caragui A; Cristian M; Constantinoiu S Chirurgia (Bucur); 2018; 113(1):38-45. PubMed ID: 29509530 [TBL] [Abstract][Full Text] [Related]
6. Individualized surgical strategies for cancer of the esophagogastric junction. Stein HJ; Feith M; Siewert JR Ann Chir Gynaecol; 2000; 89(3):191-8. PubMed ID: 11079787 [TBL] [Abstract][Full Text] [Related]
7. Advances in the treatment of gastric cancer: 2020-2021. Ilson DH Curr Opin Gastroenterol; 2021 Nov; 37(6):615-618. PubMed ID: 34456227 [TBL] [Abstract][Full Text] [Related]
8. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. Al-Batran SE; Goetze TO; Mueller DW; Vogel A; Winkler M; Lorenzen S; Novotny A; Pauligk C; Homann N; Jungbluth T; Reissfelder C; Caca K; Retter S; Horndasch E; Gumpp J; Bolling C; Fuchs KH; Blau W; Padberg W; Pohl M; Wunsch A; Michl P; Mannes F; Schwarzbach M; Schmalenberg H; Hohaus M; Scholz C; Benckert C; Knorrenschild JR; Kanngießer V; Zander T; Alakus H; Hofheinz RD; Roedel C; Shah MA; Sasako M; Lorenz D; Izbicki J; Bechstein WO; Lang H; Moenig SP BMC Cancer; 2017 Dec; 17(1):893. PubMed ID: 29282088 [TBL] [Abstract][Full Text] [Related]
9. Controversies in the treatment of local and locally advanced gastric and esophageal cancers. Cohen DJ; Leichman L J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302 [TBL] [Abstract][Full Text] [Related]
10. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975 [TBL] [Abstract][Full Text] [Related]
12. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462 [TBL] [Abstract][Full Text] [Related]
13. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis. Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Lind PA; Lindblad M; Ye W; Lundell L; Schuhmacher C; Mauer M; Burmeister BH; Thomas JM; Stahl M; Nilsson M Eur J Surg Oncol; 2015 Mar; 41(3):282-94. PubMed ID: 25491892 [TBL] [Abstract][Full Text] [Related]
14. Updated evidence on adjuvant treatments for gastric cancer. Kanda M; Kodera Y; Sakamoto J Expert Rev Gastroenterol Hepatol; 2015; 9(12):1549-60. PubMed ID: 26414453 [TBL] [Abstract][Full Text] [Related]
15. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions. Sandler S Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325 [TBL] [Abstract][Full Text] [Related]
17. Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction and proximal gastric cancers: a comparison of normal tissue radiation doses. Tillman GF; Pawlicki T; Koong AC; Goodman KA Dis Esophagus; 2008; 21(5):437-44. PubMed ID: 19125798 [TBL] [Abstract][Full Text] [Related]
18. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M; Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study. Newman E; Potmesil M; Ryan T; Marcus S; Hiotis S; Yee H; Norwood B; Wendell M; Muggia F; Hochster H Semin Oncol; 2005 Dec; 32(6 Suppl 9):S97-100. PubMed ID: 16399443 [TBL] [Abstract][Full Text] [Related]